Long-term survival after second-line therapy with docetaxel and carboplatin and monthly pamidronic acid in a woman with metastatic non-small cell lung cancer

Onkologie

Volumn 29, Issue 5, 2006, Pages 206-208

  Andritzky, Birte ^a   Schuch, Gunter ^a   Thoem, Ina ^a   Goern, Michael ^a   Brandl, Stephan ^a   Bokemeyer, Carsten ^a   Laack, Eckart ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bisphosphonate; Carboplatin; Chemotherapy; Docetaxel; Lung cancer, non small cell; Pamidronic acid; Survival, long term

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CLEMASTINE; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; NAVELBINE; ONDANSETRON; PAMIDRONIC ACID; RANITIDINE;

ADULT; ALLERGIC REACTION; ARM EDEMA; ARTICLE; BONE ATROPHY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DERMATITIS; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LEG EDEMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; NAUSEA; SPINAL CORD DECOMPRESSION; SURVIVAL TIME; SYMPTOM; THORACIC SPINE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DIPHOSPHONATES; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; TAXOIDS; TREATMENT OUTCOME;

EID: 33646498514     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092263     Document Type: Article

References (17)

1. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippmann S, Benner S, Glisson B: Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J Clin Oncol 1995;13:645-651.
2. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis D, Carbone D, Karp D, Belani C: Multicenter trial of docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): confirmation of prolonged survival. Lung Cancer 1997;18:21.
3. Robinet G, Kleisbauer JP, Thomas P, Perol M, Carles P, Paillotin D, Lena H, Poirier R, Clouet P, Lenseigne S, Soares JA: Phase II study of docetaxel (Taxotere) in first and second line NSCLC. Lung Cancer 1997;18:42.
4. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Greesot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
5. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kaiman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
6. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paletti P, Einhorn L, Bunn PA Jr: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
7. Wachters FM, van Putten JW, Boezen HM, Groen HJ: Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC. Lung Cancer 2004;45:255-262.
8. Laack E, Dierlamm T, Knuffmann C, Popp J, Schmied B, Durk H, Wacker-Backerhaus G, Zeller W, Verpoort K, Fiedler W, Kurt Hossfeld D: Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer. Lung Cancer 2002;36:303-307.
9. Saba N, Khuri F: The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses. Oncology 2005;68:18-22.
10. Bauss F, Body JJ: Ibandronate in metastatic bone disease: a review of preclinical data. Anticancer Drugs 2005;16:107-118.
11. Kuroda J, Kimura S, Segawa H, Sato K, Matsumoto S, Nogawa M, Yuasa T, Kobayashi Y, Yoshikawa T, Ottmann OG, Maekawa T: p53-independent anti-tumor effects of the nitrogen-containing bisphosphonates zoledronic acid. Cancer Sci 2004;95:186-192.
12. Kondo H, Mori A: Anti-tumor activity of pamidronate in human multiple myeloma. Leuk Lymphoma 2002;43:919-921.
13. Kondo H, Mori A, Kubota M: Maintenance with pamidronate following first-line MP or VAD therapy in multiple myeloma. Leuk Lymphoma 2003;44:303-307.
14. Aparicio A, Gardner A, Tu Y, Savage A. Berenson J, Lichtenstein A: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998;12:220-229.
15. Clezardin P, Gligorov J, Delmas P: Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis. Joint Bone Spine 2000;67:22-29.
16. Croucher P, Jagdev S, Coleman R: The anti-tumor potential of zoledronic acid. Breast 2003;12:30-36.
17. Avcu F, Ural AU, Yilmaz MI, Ozcan A, Ide T, Kurt B, Yalcin A: The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane. Eur J Haematol 2005;74:496-500.